Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1888
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma ; volume:22 ; number:1 ; day:22 ; month:1 ; year:2021 ; pages:101-115 ; date:1.2021
American journal of clinical dermatology ; 22, Heft 1 (22.1.2021), 101-115, 1.2021
- Creator
-
Bansal, Ashish
Simpson, Eric L.
Paller, Amy S.
Siegfried, Elaine C.
Blauvelt, Andrew
Bruin-Weller, Marjolein de
Corren, Jonathan
Sher, Lawrence
Guttman-Yassky, Emma
Chen, Zhen
Daizadeh, Nadia
Kamal, Mohamed A.
Shumel, Brad
Mina-Osorio, Paola
Mannent, Leda
Patel, Naimish
Graham, Neil M. H.
Khokhar, Faisal A.
Ardeleanu, Marius
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40257-020-00577-1
- URN
-
urn:nbn:de:101:1-2021032221054805833119
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bansal, Ashish
- Simpson, Eric L.
- Paller, Amy S.
- Siegfried, Elaine C.
- Blauvelt, Andrew
- Bruin-Weller, Marjolein de
- Corren, Jonathan
- Sher, Lawrence
- Guttman-Yassky, Emma
- Chen, Zhen
- Daizadeh, Nadia
- Kamal, Mohamed A.
- Shumel, Brad
- Mina-Osorio, Paola
- Mannent, Leda
- Patel, Naimish
- Graham, Neil M. H.
- Khokhar, Faisal A.
- Ardeleanu, Marius
- SpringerLink (Online service)
Other Objects (12)
Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities
Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Protein design for industrial strain development : the case of amino acid production
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities
Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Protein design for industrial strain development : the case of amino acid production
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities
Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
Protein design for industrial strain development : the case of amino acid production
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis